Faron Pharmaceuticals Oy (FARN) Competitors GBX 215 0.00 (0.00%) As of 07/4/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock FARN vs. ERGO, SLN, PRTC, OXB, HZD, VRP, ARIX, CIR, BVXP, and 4BBShould you be buying Faron Pharmaceuticals Oy stock or one of its competitors? The main competitors of Faron Pharmaceuticals Oy include Ergomed (ERGO), Silence Therapeutics (SLN), PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Circassia Group (CIR), Bioventix (BVXP), and 4basebio (4BB). These companies are all part of the "biotechnology" industry. Faron Pharmaceuticals Oy vs. Its Competitors Ergomed Silence Therapeutics PureTech Health Oxford Biomedica Horizon Discovery Group plc (HZD.L) Verona Pharma plc (VRP.L) Arix Bioscience Circassia Group Bioventix 4basebio Faron Pharmaceuticals Oy (LON:FARN) and Ergomed (LON:ERGO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability. Does the media prefer FARN or ERGO? In the previous week, Faron Pharmaceuticals Oy had 1 more articles in the media than Ergomed. MarketBeat recorded 1 mentions for Faron Pharmaceuticals Oy and 0 mentions for Ergomed. Faron Pharmaceuticals Oy's average media sentiment score of 0.00 equaled Ergomed'saverage media sentiment score. Company Overall Sentiment Faron Pharmaceuticals Oy Neutral Ergomed Neutral Do institutionals and insiders have more ownership in FARN or ERGO? 10.7% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 31.8% of Faron Pharmaceuticals Oy shares are owned by insiders. Comparatively, 18.2% of Ergomed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, FARN or ERGO? Ergomed has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFaron Pharmaceuticals OyN/AN/A-£60.23M-£37.39-5.75Ergomed£152.09M0.00£15M£0.29N/A Is FARN or ERGO more profitable? Ergomed has a net margin of 9.87% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Ergomed's return on equity of 18.08% beat Faron Pharmaceuticals Oy's return on equity.Company Net Margins Return on Equity Return on Assets Faron Pharmaceuticals OyN/A 0.46% -70.00% Ergomed 9.87%18.08%10.16% Which has more volatility & risk, FARN or ERGO? Faron Pharmaceuticals Oy has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Comparatively, Ergomed has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. SummaryErgomed beats Faron Pharmaceuticals Oy on 9 of the 11 factors compared between the two stocks. Get Faron Pharmaceuticals Oy News Delivered to You Automatically Sign up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FARN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FARN vs. The Competition Export to ExcelMetricFaron Pharmaceuticals OyBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£288.64M£127.96M£5.56B£2.96BDividend YieldN/A3.74%5.22%5.02%P/E Ratio-5.753.4027.69147.88Price / SalesN/A4,084.30389.63258,917.23Price / Cash20.0013.1936.8927.97Price / Book0.1142.828.034.61Net Income-£60.23M-£92.79M£3.18B£5.90B7 Day Performance10.54%2.49%2.93%1.04%1 Month Performance-1.83%2.58%1.72%4.36%1 Year Performance128.72%181.40%34.39%82.36% Faron Pharmaceuticals Oy Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FARNFaron Pharmaceuticals OyN/AGBX 215flatN/A+125.8%£288.64MN/A-5.7534Positive NewsGap UpERGOErgomedN/AN/AN/AN/A£701.00M£152.09M4,641.386SLNSilence TherapeuticsN/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading VolumePRTCPureTech Health3.1181 of 5 starsGBX 126.80+0.6%GBX 455+258.8%-31.2%£380.88M£521.32K-5.20300News CoveragePositive NewsInsider TradeOXBOxford Biomedica2.3134 of 5 starsGBX 320+0.5%GBX 380+18.8%+1.4%£340.16M£98.31M-2.38891Positive NewsHZDHorizon Discovery Group plc (HZD.L)N/AN/AN/AN/A£302.98M£54.63M-33.55416VRPVerona Pharma plc (VRP.L)N/AN/AN/AN/A£228MN/A-1.6822Gap UpARIXArix BioscienceN/AN/AN/AN/A£183.73M£14.16M1,290.919CIRCircassia GroupN/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap DownBVXPBioventixN/AGBX 2,723-9.8%N/A-39.0%£142.59M£13.65M17.6112Gap Down4BB4basebio2.1614 of 5 starsGBX 967.50-1.8%GBX 1,600+65.4%-37.1%£123.94M£311K-1,240.38101 Related Companies and Tools Related Companies Ergomed Alternatives Silence Therapeutics Alternatives PureTech Health Alternatives Oxford Biomedica Alternatives Horizon Discovery Group plc (HZD.L) Alternatives Verona Pharma plc (VRP.L) Alternatives Arix Bioscience Alternatives Circassia Group Alternatives Bioventix Alternatives 4basebio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:FARN) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s BIGGEST setup yet.After another undefeated quarter, “Market Wizard” Larry Benedict is sounding the alarm on a $194 trillion mark...Brownstone Research | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Faron Pharmaceuticals Oy Please log in to your account or sign up in order to add this asset to your watchlist. Share Faron Pharmaceuticals Oy With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
